CREABILIS THERAPEUTICS AND BIONUCLEON ENTER COLLABORATION AGREEMENT.

Colleretto Giacosa, Bioindustry Park Canavese, Italy - CREABILIS therapeutics SpA and Bionucleon Srl, today announced a collaboration agreement to co-develop new aptamer-based compounds against targets involved in inflammatory and autoimmune diseases.
S. Traversa, CREABILIS therapeutics’ Chief Scientific Officer, said: “This collaboration represents an important additional strengthening of the ongoing projects of CREABILIS in the research of new therapeutical agents against targets involved in inflammation.”
R. Sapio, Administrator and co-founder of Bionucleon, commented:

“We are very pleased to collaborate with CREABILIS therapeutics. We view this agreement as a great opportunity to significantly accelerate the development efforts of one of our aptamer projects and build a solid aptamer patent portfolio".
F. Conicella, Bioindustry Park’s General Manager, said: “This agreement is an excellent example of the synergy that it is possible to create among companies when they operate in a Science Park contest.”
About CREABILIS therapeutics SpA
CREABILIS therapeutics is a drug discovery and development biotech company, founded in May 2003 with the aim to discover, select, develop and bring to commercial fruition novel and highly innovative therapeutic agents.
After four years of research activity a considerable, competitive and diversified project/product portfolio has been generated. The most advanced project is related to CT327 for the topical treatment of psoriasis: a Phase I clinical trial is planned in Q3 2007.
About Bionucleon Srl
Bionucleon Srl is an Italian biopharmaceutical company, founded by three scientists (Enrico Bucci, Margherita Valente and Roberto Sapio) and Eporgen Venture Spa. Bionucleon is developing a new sequencing technology for synthetic aptamers and at the same time is building a portfolio of new aptamer-based drugs for unmet medical needs across a number of therapeutic areas including cancers and inflammation. Bionucleon is working on the identification and the pharmacological improvement of aptamers: its core activity is focused on the optimization of the pharmacological performance of aptamers.